Structure's once-daily oral drug, GSBR-1290, belongs to the same class of treatments as Novo Nordisk's blockbuster weight-loss drug Wegovy and Eli Lilly's Zepbound. Leerink analysts said in a note before the data that they expected weight loss of between 5% to 6% in the trial at the end of 12 weeks, compared with 6% to 7% from Lilly's trial of its oral weight loss drug orforglipron.
The Hop is merging its M-Line and L-Line for the nine days of Summerfest to offer quicker access to the festival grounds.
Futures loom after the stock market showed resilience Friday. Nvidia CEO Huang made a big AI speech Sunday. Tesla EV rivals stepped up sales.